It used to be that the major hurdle in getting a new drug approved was successfully completing phase 3 trials – the long-term studies needed to prove to regulators that your drug was both effective and safe. These trials can take years to run and cost hundreds of millions of dollars. Yet, despite doing successful […]

Novartis AG on Tuesday won U.S. approval for its keenly awaited new heart failure drug Entresto earlier than expected, boosting hopes for a medicine tipped by analysts to reap billions of dollars in annual sales. The Swiss drugmaker had previously said U.S. approval was likely in August. The U.S. Food and Drug Administration said in […]

Entresto, Novartis’s novel heart failure (HF) drug, gained FDA approval earlier today. The approval arrived six weeks ahead of the drug’s action date. Formerly known as LCZ 696, the drug had already received a fast track designation and an expedited review under the FDA’s priority review program. Novartis said the wholesale acquisition cost of Entresto will be $12.50 per […]

Older people who walk briskly, are moderately active in their free time, drink moderately, don’t smoke and avoid obesity may be half as likely to develop heart failure as people who don’t engage in these healthy habits, a new study suggests. Based on the findings, optimizing a few healthy lifestyle factors can cut heart failure […]

Novartis plans to test a novel pricing model with some customers when it launches its keenly awaited new heart failure drug Entresto, the Swiss company’s head of pharmaceuticals said on Tuesday. Entresto, also known as LCZ696, is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot […]

Drug developer Celladon Corp said on Friday it may liquidate itself if it were unable to find a buyer, and was suspending development of its gene therapy for heart failure. The company’s shares fell 38 percent to $1.36 in premarket trading. Celladon said if it were to liquidate during the third quarter ending September, the […]